Literature DB >> 30860383

Pharmacokinetics, Pharmacodynamics, and PKPD Modeling of Curcumin in Regulating Antioxidant and Epigenetic Gene Expression in Healthy Human Volunteers.

David Cheng1,2, Wenji Li1,3, Lujing Wang1,2, Tiffany Lin1, George Poiani4,5, Andrew Wassef1, Rasika Hudlikar1, Patricia Ondar6, Luigi Brunetti1,5,7, Ah-Ng Kong1.   

Abstract

Curcumin is a major component of the spice turmeric ( Curcuma longa), often used in food or as a dietary supplement. Many preclinical studies on curcumin suggest health benefits in many diseases due to its antioxidant/anti-inflammatory and epigenetic effects. The few human studies and curcumin's unfavorable pharmacokinetics (PK) have limited its potential, leading researchers to study and develop formulations to improve its PK. The purpose of this clinical study is to describe the acute pharmacokinetics and pharmacodynamics (PK/PD) of commercially marketed curcumin in normal, healthy human volunteers. Twelve volunteers received a 4 g dose of curcumin capsules with a standard breakfast. Plasma samples were collected at specified time points and analyzed for curcumin and its glucuronide levels. RNA was extracted from leukocytes and analyzed for expression of select antioxidant and epigenetic histone deacetylase (HDAC) genes. Plasma levels of parent curcumin were below the detection limit by HPLC-ITMS/MS/MS. However, curcumin-O-glucuronide (COG), a major metabolite of curcumin, was detected as soon as 30 min. These observations of little to no curcumin and some levels of metabolite are in line with previous studies. PD marker antioxidant genes NRF2, HO-1, and NQO1 and epigenetic genes HDAC1, HDAC2, HDAC3, and HDAC4 were quantified by qPCR. COG PK is well-described by a one-compartment model, and the PK/PD of COG and its effect on antioxidant and epigenetic gene expression are captured by an indirect response model (IDR). A structural population PK model was sequentially established using a nonlinear mixed-effect model program (Monolix Lixoft, Orsay, France). Physiologically based pharmacokinetic modeling (PBPK) and simulation using Simcyp correlated well with the observed data. Taken together, these results show that the bioavailability of the parent curcumin compound is low, and oral administration of curcumin can still deliver detectable levels of curcumin glucuronide metabolite. But most importantly, it elicits antioxidant and epigenetic effects which could contribute to the overall health beneficial effects of curcumin.

Entities:  

Keywords:  NRF2; curcumin; inflammation; oxidative stress; pharmacokinetics/pharmacodynamics

Mesh:

Substances:

Year:  2019        PMID: 30860383      PMCID: PMC6710832          DOI: 10.1021/acs.molpharmaceut.8b01246

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  51 in total

1.  Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies.

Authors:  Gamze Bora-Tatar; Didem Dayangaç-Erden; Ayhan S Demir; Sevim Dalkara; Kemal Yelekçi; Hayat Erdem-Yurter
Journal:  Bioorg Med Chem       Date:  2009-05-23       Impact factor: 3.641

2.  Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics.

Authors:  Y N Sun; W J Jusko
Journal:  J Pharm Sci       Date:  1998-06       Impact factor: 3.534

3.  Metabolism and permeability of curcumin in cultured Caco-2 cells.

Authors:  Julia S Dempe; Romy K Scheerle; Erika Pfeiffer; Manfred Metzler
Journal:  Mol Nutr Food Res       Date:  2012-08-29       Impact factor: 5.914

4.  Pharmacodynamics of ginsenosides: antioxidant activities, activation of Nrf2, and potential synergistic effects of combinations.

Authors:  Constance Lay Lay Saw; Anne Yuqing Yang; David C Cheng; Sarandeep S-S Boyanapalli; Zheng-Yuan Su; Tin Oo Khor; Song Gao; Jingrong Wang; Zhi-Hong Jiang; Ah-Ng Tony Kong
Journal:  Chem Res Toxicol       Date:  2012-08-09       Impact factor: 3.739

5.  Curcumin Ameliorates Kidney Function and Oxidative Stress in Experimental Chronic Kidney Disease.

Authors:  Badreldin H Ali; Suhail Al-Salam; Yousuf Al Suleimani; Jamila Al Kalbani; Shadia Al Bahlani; Mohammed Ashique; Priyadarsini Manoj; Buthaina Al Dhahli; Nadia Al Abri; Heba T Naser; Javed Yasin; Abderrahim Nemmar; Mohammed Al Za'abi; Christina Hartmann; Nicole Schupp
Journal:  Basic Clin Pharmacol Toxicol       Date:  2017-07-10       Impact factor: 4.080

6.  Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1.

Authors:  Yue Guo; Limin Shu; Chengyue Zhang; Zheng-Yuan Su; Ah-Ng Tony Kong
Journal:  Biochem Pharmacol       Date:  2015-01-29       Impact factor: 5.858

7.  Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects.

Authors:  Shaiju K Vareed; Madhuri Kakarala; Mack T Ruffin; James A Crowell; Daniel P Normolle; Zora Djuric; Dean E Brenner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-06       Impact factor: 4.254

8.  Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway.

Authors:  Constanze Buhrmann; Ali Mobasheri; Franziska Busch; Constance Aldinger; Ralf Stahlmann; Azadeh Montaseri; Mehdi Shakibaei
Journal:  J Biol Chem       Date:  2011-06-13       Impact factor: 5.157

9.  Dose escalation of a curcuminoid formulation.

Authors:  Christopher D Lao; Mack T Ruffin; Daniel Normolle; Dennis D Heath; Sandra I Murray; Joanne M Bailey; Martha E Boggs; James Crowell; Cheryl L Rock; Dean E Brenner
Journal:  BMC Complement Altern Med       Date:  2006-03-17       Impact factor: 3.659

10.  Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration.

Authors:  G Garcea; D J L Jones; R Singh; A R Dennison; P B Farmer; R A Sharma; W P Steward; A J Gescher; D P Berry
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

View more
  16 in total

1.  Pharmacokinetics and pharmacodynamics of three oral formulations of curcumin in rats.

Authors:  Lujing Wang; Wenji Li; David Cheng; Yue Guo; Renyi Wu; Ran Yin; Shanyi Li; Hsiao-Chen Kuo; Rasika Hudlikar; Hilly Yang; Brian Buckley; Ah-Ng Kong
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-02-04       Impact factor: 2.745

Review 2.  Regulation of Gene Expression through Food-Curcumin as a Sirtuin Activity Modulator.

Authors:  Anca Ungurianu; Anca Zanfirescu; Denisa Margină
Journal:  Plants (Basel)       Date:  2022-06-30

Review 3.  Epigenetics/epigenomics and prevention by curcumin of early stages of inflammatory-driven colon cancer.

Authors:  Renyi Wu; Lujing Wang; Ran Yin; Rasika Hudlikar; Shanyi Li; Hsiao-Chen D Kuo; Rebecca Peter; Davit Sargsyan; Yue Guo; Xia Liu; A N Kong
Journal:  Mol Carcinog       Date:  2019-12-09       Impact factor: 4.784

Review 4.  Redox signaling, mitochondrial metabolism, epigenetics and redox active phytochemicals.

Authors:  Renyi Wu; Shanyi Li; Rasika Hudlikar; Lujing Wang; Ahmad Shannar; Rebecca Peter; Pochung Jordan Chou; Hsiao-Chen Dina Kuo; Zhigang Liu; Ah-Ng Kong
Journal:  Free Radic Biol Med       Date:  2020-12-24       Impact factor: 7.376

5.  In Silico Prediction of Intestinal Permeability by Hierarchical Support Vector Regression.

Authors:  Ming-Han Lee; Giang Huong Ta; Ching-Feng Weng; Max K Leong
Journal:  Int J Mol Sci       Date:  2020-05-19       Impact factor: 5.923

6.  Synthesis, Biochemical Characterization, and Theoretical Studies of Novel β-Keto-enol Pyridine and Furan Derivatives as Potent Antifungal Agents.

Authors:  Said Tighadouini; Smaail Radi; Redouane Benabbes; Moulay Hfid Youssoufi; Sergey Shityakov; Mohamed El Massaoudi; Yann Garcia
Journal:  ACS Omega       Date:  2020-07-09

Review 7.  Quercetin, Epigallocatechin Gallate, Curcumin, and Resveratrol: From Dietary Sources to Human MicroRNA Modulation.

Authors:  Erika Cione; Chiara La Torre; Roberto Cannataro; Maria Cristina Caroleo; Pierluigi Plastina; Luca Gallelli
Journal:  Molecules       Date:  2019-12-23       Impact factor: 4.411

Review 8.  Epigenetics/Epigenomics and Prevention of Early Stages of Cancer by Isothiocyanates.

Authors:  Rasika Hudlikar; Lujing Wang; Renyi Wu; Shanyi Li; Rebecca Peter; Ahmad Shannar; Pochung Jordan Chou; Xia Liu; Zhigang Liu; Hsiao-Chen Dina Kuo; Ah-Ng Kong
Journal:  Cancer Prev Res (Phila)       Date:  2020-10-14

Review 9.  Curcumin-A Viable Agent for Better Bladder Cancer Treatment.

Authors:  Jochen Rutz; Andrea Janicova; Katja Woidacki; Felix K-H Chun; Roman A Blaheta; Borna Relja
Journal:  Int J Mol Sci       Date:  2020-05-26       Impact factor: 5.923

Review 10.  Curcumin: Could This Compound Be Useful in Pregnancy and Pregnancy-Related Complications?

Authors:  Tiziana Filardi; Rosaria Varì; Elisabetta Ferretti; Alessandra Zicari; Susanna Morano; Carmela Santangelo
Journal:  Nutrients       Date:  2020-10-17       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.